tiprankstipranks
Panbela Therapeutics, Inc. (PBLA)
:PBLA
US Market
Holding PBLA?
Track your performance easily

Panbela Therapeutics (PBLA) Earnings Dates, Call Summary & Reports

244 Followers

Earnings Data

Report Date
Mar 20, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Based on 0 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 14, 2019
|
% Change Since: 26.67%
|
Next Earnings Date:Mar 22, 2019
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in clinical trials and strategic investments, balanced by financial challenges and cash flow concerns. The strategic investment from Nant Capital and progress in clinical trials were notable positives, but the financial challenges indicate ongoing risks.
Company Guidance
During the Panbela Therapeutics Q3 2024 earnings call, the company provided several key guidance metrics. Jennifer Simpson, the CEO, highlighted a $12 million strategic loan commitment from Nant Capital, with $2.85 million already funded and an additional $9.15 million expected by November 15. The company is advancing its Phase III ASPIRE global clinical trial, targeting full enrollment of approximately 600 patients by Q2 2025, and anticipates an interim analysis in Q1 2025. Additionally, general and administrative expenses were stable at $1.1 million, while research and development expenses decreased slightly to $6.1 million from the prior year. The net loss for the quarter was $7.2 million, with cash reserves at about $142,000 as of September 30, not reflecting the recent funding. The guidance emphasized the strategic importance of ongoing clinical developments and the financial backing to support future advancements.
Strategic Investment from Nant Capital
A $12 million strategic loan commitment from Nant Capital, consisting of two tranches of convertible promissory notes, demonstrating confidence in Panbela's multi-targeted approach to pancreatic cancer treatment.
ASPIRE Trial Progress
The Phase III ASPIRE global clinical trial for metastatic pancreatic ductal adenocarcinoma is showing a notably lower event rate, potentially signaling better patient outcomes and a significant advance over current standards of care.
Eflornithine FDA Approval
Eflornithine received FDA approval, marking the first FDA-approved polyamine-targeted therapy in cancer, validating Panbela's polyamine-focused approach.
Advancements in Clinical Pipeline
Progress in Phase II and Phase I trials, including the eflornithine study in prostate cancer and the initiation of a study for STK11 mutant non-small cell lung cancer.
---

Panbela Therapeutics (PBLA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PBLA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 22, 20192018 (Q4)
- / -6.57
-23.271.68% (+16.63)
May 14, 20192019 (Q1)
- / -12.47
-1830.73% (+5.53)
Aug 13, 20192019 (Q2)
- / -537.48
-64817.06% (+110.52)
Nov 13, 20192019 (Q3)
- / -274.34
-219.816-24.81% (-54.53)
Mar 24, 20202019 (Q4)
- / -3525.12
-3942.7210.59% (+417.60)
May 12, 20202020 (Q1)
- / -6507.36
-7480.5613.01% (+973.20)
Aug 11, 20202020 (Q2)
- / -1440.00
-10749.686.60% (+9309.60)
Nov 12, 20202020 (Q3)
- / -5040.00
-5486.888.14% (+446.88)
Mar 25, 20212020 (Q4)
- / -2160.00
-3525.1238.73% (+1365.12)
May 12, 20212021 (Q1)
-2640.00 / -5520.00
-6507.3615.17% (+987.36)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

PBLA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 14, 2024$0.30$0.32+6.67%
Aug 13, 2024$0.35$0.350.00%
May 15, 2024$0.40$0.48+20.00%
Mar 26, 2024$0.64$0.67+4.69%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Panbela Therapeutics, Inc. (PBLA) report earnings?
Panbela Therapeutics, Inc. (PBLA) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
    What is Panbela Therapeutics, Inc. (PBLA) earnings time?
    Panbela Therapeutics, Inc. (PBLA) earnings time is at Mar 20, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PBLA EPS forecast?
          Currently, no data Available
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis